女性非吸烟肺腺癌患者癌组织中 miR-93-3p 表达与 EGFR 突变的关系.

Objective To investigate the relationship between the mutation of epidermal growth factor receptor (EGFR) and the relative expression of miR-93-3p in lung adenocarcinoma tissues from non-smoking female patients. Methods Totally 149 cases of non-smoking female patients with lung adenocarcinoma were selected. The expression levels of miR-93-3p in lung adenocarcinoma tissues from 112 cases of 149 patients were detected by real-time quantitative PCR. EGFR mutations were detected in 149 patients using DNA sequencing, and then we analyzed correlations of miR-93-3p expression with the clinicopathological features, EGFR mutation and prognosis. Results The relative expression of miR-93-3p was associated with the clinical stage. The miR-93-3p EGFR mutations were found in 71 of 149 patients (47. 65%). The relative expression of miR-93-3p in patients with EGFR mutations were higher than that of patients with wild type (P < 0. 01). There was no significant difference in prognosis between the patients with high and low expression of miR-93-3p, although the patients with high expression showed a poorer prognosis (P > 0. 05). Stratified analysis revealed that for patients younger than 60 years old, higher levels of miR-93-3 pexpression indicated worse prognosis (P < 0. 05). Conclusion The expression of miR-93-3p is increased in patients with EGFR mutations, which suggests that miR-93-3p may be a new therapeutic target for the treatment of non-smoking female patients with lung adenocarcinoma, especially for young female ones. [ABSTRACT FROM AUTHOR]